BACKGROUND: This study evaluated dissolvable microneedle patch (dMNP) delivery of hepatitis B vaccine in rhesus macaques and provides evidence that dMNP delivery elicits seroprotective anti-HBs levels comparable with human seroprotection, potentially useful for hepatitis B birth dose vaccination in resource-constrained regions. METHODS: Sixteen macaques were each vaccinated twice; they were treated in 4 groups, with dMNP delivery of AFV at 24 ± 8 µg (n = 4) or 48 ± 14 µg (n = 4), intramuscular injection of AFV (10 µg; n = 4), or intramuscular injection of AAV (10 µg; n = 4). Levels of antibody to hepatitis B surface antigen (HBsAg) (anti-HBs) and HBsAg-specific T-cell responses were analyzed. RESULTS: Six of 8 animals with dMNP delivery of AFV had anti-HBs levels ≥10 mIU/mL after the first vaccine dose. After dMNP delivery of AFV, interferon γ, interleukin 2, and interleukin 4 production by HBsAg-specific T cells was detected. A statistically significant positive correlation was detected between anti-HBs levels and cells producing HBsAg-specific interferon γ and interleukin 2 (T-helper 1-type cytokine) and interleukin 4 (T-helper 2-type cytokine) in all anti-HBs-positive animals. CONCLUSIONS: dMNP delivery of AFV can elicit seroprotective anti-HBs levels in rhesus macaques that are correlated with human seroprotection, and it could be particularly promising for birth dose delivery of hepatitis B vaccine in resource-constrained regions. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: This study evaluated dissolvable microneedle patch (dMNP) delivery of hepatitis B vaccine in rhesus macaques and provides evidence that dMNP delivery elicits seroprotective anti-HBs levels comparable with human seroprotection, potentially useful for hepatitis B birth dose vaccination in resource-constrained regions. METHODS: Sixteen macaques were each vaccinated twice; they were treated in 4 groups, with dMNP delivery of AFV at 24 ± 8 µg (n = 4) or 48 ± 14 µg (n = 4), intramuscular injection of AFV (10 µg; n = 4), or intramuscular injection of AAV (10 µg; n = 4). Levels of antibody to hepatitis B surface antigen (HBsAg) (anti-HBs) and HBsAg-specific T-cell responses were analyzed. RESULTS: Six of 8 animals with dMNP delivery of AFV had anti-HBs levels ≥10 mIU/mL after the first vaccine dose. After dMNP delivery of AFV, interferon γ, interleukin 2, and interleukin 4 production by HBsAg-specific T cells was detected. A statistically significant positive correlation was detected between anti-HBs levels and cells producing HBsAg-specific interferon γ and interleukin 2 (T-helper 1-type cytokine) and interleukin 4 (T-helper 2-type cytokine) in all anti-HBs-positive animals. CONCLUSIONS:dMNP delivery of AFV can elicit seroprotective anti-HBs levels in rhesus macaques that are correlated with human seroprotection, and it could be particularly promising for birth dose delivery of hepatitis B vaccine in resource-constrained regions. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Entities:
Keywords:
adaptive immune response; cellular immune response; hepatitis B vaccine; hepatitis B virus; microneedle patch; rhesus macaques; skin vaccination
Authors: Michael W Munks; Amy S McKee; Megan K Macleod; Roger L Powell; Jay L Degen; Nichole A Reisdorph; John W Kappler; Philippa Marrack Journal: Blood Date: 2010-09-27 Impact factor: 22.113
Authors: Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz Journal: Lancet Date: 2017-06-27 Impact factor: 79.321
Authors: Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward Journal: MMWR Recomm Rep Date: 2006-12-08
Authors: Maria del Pilar Martin; William C Weldon; Vladimir G Zarnitsyn; Dimitrios G Koutsonanos; Hamed Akbari; Ioanna Skountzou; Joshy Jacob; Mark R Prausnitz; Richard W Compans Journal: mBio Date: 2012-03-06 Impact factor: 7.867
Authors: Monica B Perez Cuevas; Maja Kodani; Youkyung Choi; Jessica Joyce; Siobhan M O'Connor; Saleem Kamili; Mark R Prausnitz Journal: Bioeng Transl Med Date: 2018-08-27
Authors: Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo Journal: Expert Opin Drug Deliv Date: 2020-10-06 Impact factor: 8.129
Authors: Rayen Yanara Valdivia-Olivares; Maria Rodriguez-Fernandez; María Javiera Álvarez-Figueroa; Alexis M Kalergis; José Vicente González-Aramundiz Journal: Vaccines (Basel) Date: 2021-12-01